-+ 0.00%
-+ 0.00%
-+ 0.00%
Sandoz partners with Adalvo to commercialize semaglutide in Brazil after ANVISA approval
Share
Listen to the news
Sandoz partners with Adalvo to commercialize semaglutide in Brazil after ANVISA approval
  • Sandoz secured marketing authorization in Brazil for Owozy (semaglutide) to be commercialized through a partnership with Adalvo.
  • Deal gives Sandoz commercial rights in an estimated USD 1.8 billion Brazilian GLP-1 market.
  • Launch targeted for the second half of 2026; product uses a pre-filled multi-dose disposable pen.
  • Sandoz expects no material 2026 financial contribution from any potential generic semaglutide launch.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sandoz Group AG published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2373154_en) on July 29, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending